A potential role angiotensin II-induced vascular endothelial growth factor expression in the pathogenesis of diabetic nephropathy?

Mineral and Electrolyte Metabolism

Volumn 24, Issue 6, 1998, Pages 400-405

  Williams, Bryan ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Angiotensin II; Diabetes; Nephropathy; Retinopathy; VEGF

Indexed keywords

ANGIOTENSIN; VASCULOTROPIN;

ANGIOGENESIS; BLOOD VESSEL PERMEABILITY; COMORBIDITY; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN SYNTHESIS REGULATION; REVIEW;

ANGIOTENSIN II; ANIMALS; DIABETIC NEPHROPATHIES; DIABETIC RETINOPATHY; ENDOTHELIAL GROWTH FACTORS; HUMANS; KIDNEY; LYMPHOKINES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0032413888     PISSN: 03780392     EISSN: None     Source Type: Journal    
DOI: 10.1159/000057401     Document Type: Review

References (45)

1. Ferrara N, Houck K, Jakeman L, Leung DW: Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev 1992;13:18-22.
2. Senger DR, Van Der Water L, Brown LF: Vacular permeability factor in tumour biology. Cancer Metastases Rev 1993;12:303-324.
3. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD (The Collaborative Study Group): The effect of angiotensin converting enzyme inhibition of diabetic nephropathy. N Engl J Med 1993;329: 1446-1462.
4. Kasiske B, Kalil R, Ma J, Liao M, Keane W: Effect of antihypertensive therapy on the kidney in patients with diabetes: A meta-regression analysis. Ann Intern Med 1993;118:129-138.
5. Laffel LM, McGill JB, Gans DJ: The beneficial effect of angiotensin converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria: North American Microalbuminuria Study Group. Am J Med 1995;99:497-504.
6. Cooper ME, Allen TJ, Macmillan PA, Clarke BE, Jerums G, Doyle AE: Enalapril retards glomerular basement membrane thickening and albuminuria in the diabetic rat. Diabetologia 1989;32:326-328.
7. Zatz R, Dunn BR, Meyer TW, Brenner B: Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 1986;77:1925-1930.
8. The EUCLID Study Group: Randomised placebo-controlled trial of lisinopril in normotensive patients with IDDM and normoalbuminuria or microalbuminuria. Lancet 1997;349:1787-1792.
9. Blantz RC, Gabbai FB: Effect of angiotensin II on glomerular haemodynamics and ultrafiltration coefficient. Kidney Int 1987;31(suppl20): 108-111.
10. Tufro-McReddie A, Romano LM, Harris JM, Ferder L, Gomez A: Angiotensin II regulates nephrogenesis and renal vascular development. Am J Physiol 1995;269:F110-F115.
11. Gilbert RE, Cox A, Wu LL, Allen TJ, Lennart Hulthen U, Jerums G, Cooper ME: Expression of transforming growth factor β1 and type IV collagen in the renal tubulointerstitium in experimental diabetes: Effects of ACE inhibition. Diabetes 1998;47:414-422.
12. Danser AJH, Van Den Dorpel NA, Deinum J, et al: Renin, pro-renin and immunoreactive renin in vitreous fluid from eyes with and without diabetic retinopathy. J Clin Endocrinol Metab 1989;68:160-167.
13. Lai KN, Leung JCK, Lai KB, To WY, Yeung VTE, Lai FMM: Gene expression of the reninangiotensin system in human kidney. J Hypertens 1998;16:91-102.
14. Chaturvedi N, Sjolie A-K, Stephenson JM, et al: Effects of lisinopril on progression of retinopathy in normotensive people with type I diabetes. Lancet 1998;351:225-231.
15. Williams B, Baker A-Q, Gallacher B, Lodwick D: Angiotensin II increases vascular permeability factor gene expression by human vascular smooth muscle. Hypertension 1995;68:160-167.
16. Williams B: Angiotensin II, VEGF, and diabetic retinopathy. Lancet 1998;351:837-838.
17. Williams B: Vascular permeability/endothelial growth factors: A potential role in the pathogenesis and treatment of vascular diseases. Vasc Med 1996;1:251-258.
18. Van der Zee R, Murohara T, Luo Z, et al: Vascular endothelial growth factor/vascular permeability factor augments nitric oxide release from quiescent rabbit and human vascular endothelium. Circulation 1997;95:1030-1037.
19. Olofsson B, Pajusola K, Kaipainen A, et al: Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc Natl Acad Sci USA 1996;93:2567-2581.
20. Joukov V, Pajusola K, Chilov D, et al: A novel vascular endothelial growth factor, VEGF-C. is a ligand for Flt-4 (VEGF-R3) and KDR (VEGF-R2) receptor tyrosine kinases. EMBO J 1996;15:290-298.
21. Yamada Y, Nezu J, Shimane M, Hirata Y: Molecular cloning of a novel vascular endothelial growth factor. VEGF-D. Genomics 1997;42: 483-488.
22. Jakeman LB, Winer J, Bennet GL, Altar CA, Ferrara N: Binding sites for vascular endothelial growth factor are localized to endothelial cells in adult rat tissues. J Clin Invest 1992;89:244-253.
23. Lee J, Gray A, Yuan J, Luoh S, Avraham H, Wood WI: Vascular endothelial growth factor-related protein: A ligand and specific activator of the tyrosine Flt-4. Proc Natl Acad Sci USA 1996;93:1988-1992.
24. Simon M, Grone HJ, Johren O, et al: Expression of vascular endothelial growth factor and its receptors in human renal ontogenesis and in adult kidney. Am J Physiol 1995;268:F240-F250.
25. Whittle C, Mathieson P, Harper SJ: Vascular permeability factor mRNA isoform and receptor expression in isolated single human glomeruli. Proc British Renal Association, March 1998, p 38.
26. Iijima K, Yoshikawa N, Connolly DT, Nakamura H: Human mesangial cells and peripheral blood mononuclear cells produce vascular permeability factor. Kidney Int 1993;44:959-966.
27. Barleon B, Sozzani S, Zhou D, Weich HA, Mantovani A, Marme D: Migration of human monocytes in response to vascular endothelial growth factor is mediated by the Flt-1 receptor. Blood 1996;87:3336-3343.
28. Tufro-McReddie A, Norwood VF, Aylor KW, Botkin SJ, Carey RM, Gomez RA: Oxygen regulates vascular endothelial growth factor-mediated vasculogenesis and tubulogenesis. Dev Biol 1997;183:139-149.
29. Kitamoto Y, Tokunaga H, Tomita K: Vascular endothelial growth factor is an essential molecule for mouse kidney development: Glomerulogenesis and nephrogenesis. J Clin Invest 1997; 99:2351-2357.
30. Williams B: Factors regulating the expression of vascular permeability/vascular endothelial growth factor by human vascular tissues. Diabctologia 1997;40:5118-S120.
31. Shuman K, Rosen S, Tognazzi K, Manseau EJ, Brown LF: Expression of vascular permeability factor (VPF/VEGF) is altered in many glomerular diseases. J Am Soc Nephrol 1996;7:661-666.
32. Shweiki D, Itin A, Solfer D, Keshet E: Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992;359:843-845.
33. Williams B, Baker A-Q, Gallacher B, Lodwick D: Angiotensin II increases vascular permeability factor gene expression by human vascular smooth muscle. Hypertension 1995;68:160-167.
34. Williams B, Gallacher B, Patel H, Orme C: The potential role of vasopressin as a modulator of endothelial function: in Saito T, Kurokawa K, Yoshida S (eds): Neurohypophysis: Recent Progress of Vasopressin and Oxytocin Research. Amsterdam, Elsevier Science, 1995, pp 573-582.
35. Brogi E, Wu T, Namiki A, Isner JM: Indirect angiogenic cytokines upregulate VEGF and bFGF gene expression in vascular smooth muscle cells, whereas hypoxia upregulates VEGF only. Circulation 1994;90:649-652.
36. Stavri GT, Zachary IC, Baskerville PA, Martin JF, Erusalimsky JD: Basic fibroblast growth factor upregulates the expression of vascular endothelial growth factor in vascular smooth muscle cells: Synergistic interaction with hypoxia. Circulation 1995;92:11-14.
37. Williams B, Quinn Baker A, Gallacher B: Serum and platelet-derived growth factor-induced vascular permeability factor mRNA expression by human vascular smooth muscle cells in vitro. Clin Sci 1995;88:141-147.
38. Ryuoto M, Ono M, Izumi H, et al: Induction of vascular endothclial growth factor by tumour necrosis factor alpha in human glioma cells: Possible roles of Sp-1. J Biol Chem 1996;271: 28220-28228.
39. Williams B, Gallacher B, Patel H, Orme C: Glucose-induced protein kinasc C activation regulates vascular permeability factor mRNA expression and pcptide production by human vascular smooth muscle cells in vitro. Diabetes 1997;46:1497-1503.
40. Hammes H-P, Lin J, Bretzel RG, Brownlee M, Breier G: Upregulation of the vascular endothelial growth factor/vascular endothelial growth factor receptor system in experimental background diabetic retinopathy of the rat. Diabetes 1998;47:401-406.
41. Unger T, Chung O, Csikos T, et al: Angiotensin receptors. J Hypertens 1996;14(suppl 4):95-103.
42. Aiello LP, Avery RL, Arrigg PG, et al: Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331:1480-1487.
43. Aiello LP, Pierce EA, Foley ED, et al: Suppression of retinal neovascularisation in vivo by suppression of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA 1995;92: 10457-10461.
44. Robinson GS, Pierce EA, Rook SL, Foley ED, Webb R, Smith LEH: Oligodeoxynucleotides inhibit retinal neovascularisation in a murine model of proliferative retinopathy. Proc Natl Acad Sci USA 1996;93:4851-4856.
45. Kendall RL, Wang G, Thomas KA: Identification of a natural soluble form of the VEGF receptor Flt-1 and its heterodimerization with KDR. Biochem Biophys Res Commun 1996; 226:324-428.